Ads
related to: simvastatin 80 mg not recommended dosage- Co-Pay Program
Resources
to Support Your Patients
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Trial Results
See Clinical Data
and Trial
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Co-Pay Program
consumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Serious side effects may include muscle breakdown, liver problems, and increased blood sugar levels. [4] A lower dose may be needed in people with kidney problems. [4] There is evidence of harm to the developing baby when taken during pregnancy [4] [5] and it should not be used by those who are breastfeeding. [4]
The number needed to treat in the study was 57 to postpone one death and 19 to prevent one cardiovascular "event" (in those taking the drug simvastatin for 5 years). There was no mortality benefit in women with a statistical "p-value" that did not reach significance (0.08) while the Kaplan-Meier mortality curves, for men and women separately ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL (4.9 mmol/L) or those with diabetes, age 40–75 with LDL-C 70–190 mg/dL (1.8–4.9 mmol/dL); or in those with a 10-year risk of developing ...
Sitagliptin: Using male and female rats, a two-year carcinogenicity study was carried out with doses of 50, 150, and 500 mg/kg/day. The 500 mg/kg dose has exposure limits of 60 times what would be seen in the highest dose in humans. At this dose, liver adenoma/carcinoma was seen. Tumors were not seen from the smaller doses.
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
[citation needed] Annual cost to the UK National Health Service (NHS) in 2018, for 5–40 mg rosuvastatin daily (of one person) was £24-40, compared to £10-20 for 20–80 mg simvastatin. [ 38 ] In 2013, it was the fourth-highest-selling drug in the United States, accounting for approximately $5.2 billion in sales. [ 39 ]
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.